WITTEN, Germany, December 12, 2011 /PRNewswire/ --
Sangui enters commercialization phase / Initial order of Sangui developed wound spray
The Mexican State of Tamaulipas has issued an initial order of Hemo2Spray, the Sangui developed wound spray, as well as of the wound debridement product Scabremove both registered by the Mexican authorities in September this year. This is the first regular commercial order of the wound spray and Sangui management is positive that an era of innovative product development, testing and authorization will now come to fruition.
The medical product will initially be used in three state owned hospitals. While it will serve to treat patients suffering from chronic wounds its use in actual treatments will particularly be part of a comprehensive training program for doctors from other locations in Tamaulipas. The State health authorities have expressed their intent to apply the Sangui developed wound therapy in the 22 hospitals under their direction and start now in cooperation with Sangui medical staff to instruct and train their medical personnel. Global licensee SastoMed GmbH which is in charge of wound management operations expects that demand for the product will ramp up quickly when experienced doctors start treating patients throughout the state and as other Mexican states follow suit. Invoicing is to occur at short notice while shipment of the product is scheduled for early January 2012.
SanguiBioTech GmbH is a ninety percent owned subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from th
|SOURCE Sangui Bio Tech International Inc.|
Copyright©2010 PR Newswire.
All rights reserved